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Increasing evidence demonstrates that ultraviolet A radi-
ation (UVA) contributes to photoaging, which results in
the accumulation of massive amounts of abnormal elastic
material in the dermis of photoaged skin. To study UVA-
induced photoaging in an in vivo system, we utilized a
line of transgenic mice containing the human elastin
promoter linked to a chloramphenicol acetyl transferase
reporter gene. Our prior work demonstrates promoter
activation in response to ultraviolet B radiation (UVB),
UVA, and psoralen plus ultraviolet A radiation in the skin
of these mice. The addition of psoralen (8-MOP) prior
to administration of UVA results in substantial increases
in promoter activation, as compared with UVA alone.
To demonstrate the utility of these mice as a model
of UVA-induced photodamage, we administered four
lotions to the skin of our transgenic mice that included:
Most of the characteristics associated with an agedappearance are the result of cutaneous photodamageand not chronologic aging (Gilchrest, 1989). Theclinical signs of photoaging result from structuralalterations occurring in the epidermis and dermis
of sun-damaged skin. The major histopathologic change in the dermis
of photoaged skin is the accumulation of massive amounts of abnormal
elastic tissue, termed solar elastosis (Mitchell, 1967; Kligman, 1969;
Frances and Robert, 1984; Gilchrest, 1989; Montagna et al, 1989;
Taylor et al, 1990; Warren et al, 1991; Bernstein et al, 1994). Although
the role of ultraviolet B radiation (UVB) in the production of solar
elastosis, and thus photoaging, is well established, ultraviolet A radiation
(UVA) is increasingly emerging as a contributing factor (Urbach, 1992/
1993). UVA has been shown to contribute to numerous effects of solar
radiation, including the generation of erythema (Parrish et al, 1982;
Mckinlay and Diffey, 1987), the production of DNA damage (Peak
and Peak, 1992), skin cancer induction (Cole et al, 1986; deGruijl et al,
1993), and the damaging of dermal elastic fibers and the production
of solar elastosis (Johnston et al, 1984; Kligman and Sayre, 1990; Lavker
et al, 1995a, b; Lowe et al, 1995).
Using a murine model of photodamage, investigators have demon-
strated increased elastin production, as measured by desmosine, an
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a sunscreen containing octyl methoxycinnamate and
benzophenone-3 with a sun protection factor (SPF) of
15, the UVA filter butyl methoxydibenzoylmethane, the
SPF 15 sunscreen and the UVA filter together, and the
lotion vehicle alone. Following sunscreen administration,
mice received a single psoralen plus ultraviolet A radiation
treatment. All sunscreens decreased chloramphenicol
acetyl transferase activity with the SPF 15 sunscreen, the
UVA filter, and the combination SPF 15 sunscreen and
UVA filter, resulting in increasing degrees of protection
against psoralen plus ultraviolet A radiation. These results
demonstrate that this model functions as a rapid and
sensitive model of UVA photodamage for the identifica-
tion and comparison of compounds that protect against
UVA-induced photoaging. Key words: aging/elastosis/
mouse/sunscreen. J Invest Dermatol 110:343–347, 1998
elastin-specific crosslink compound, in response to UVA after a total
of 30 d of intermittent UVA treatments (Johnston et al, 1984).
Mouse models measuring the generation of solar elastosis, detected by
histopathologic examination, in response to UVA required far longer
treatment times to develop detectable amounts of solar elastosis
(Kligman et al, 1985; Bissett et al, 1987, 1989; Wulf et al, 1989;
Kligman and Sayre, 1990; Fourtanier et al, 1992). To develop a more
rapid and sensitive model for studying UVA-induced photoaging and
for testing compounds that may protect against UVA damage, we
utilized a transgenic mouse line containing the human elastin promoter
linked to a chloramphenicol acetyltransferase (CAT) reporter gene
(Hsu-Wong et al, 1994; Bernstein et al, 1995, 1996). These mice are
phenotypically normal and indistinguishable from mice of the same
strain without the transgene. Because CAT is a bacterial enzyme not
normally present in mammalian cells, its level reflects the degree of
elastin gene induction in cells containing the elastin promoter/CAT
construct. Measurement of elastin gene induction in response to a
single exposure of UVA or UVB is possible with these mice, a degree
of sensitivity not achievable when measuring elastin protein production
or the amount of solar elastosis present. We previously demonstrated
elastin promoter activation in the skin of these mice in response to a
single exposure of UVA and UVB (Bernstein et al, 1995); however, in
contrast to the large 8.5-fold increase in CAT activity measured in
response to UVB, promoter induction after UVA exposure reached
only 1.8-fold that of controls (Bernstein et al, 1995). To determine if
the addition of 8-MOP prior to UVA treatment would increase
promoter activation, we subsequently treated mice with psoralen plus
ultraviolet A radiation (PUVA) and demonstrated a 3.3-fold increase
in elastin promoter activation in vivo, almost doubling the response
elicited by UVA alone (Bernstein et al, 1996). Further increases in
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Figure 1. Emission spectrum of the PUVA lamps filtered through
window glass. UVA is emitted with almost no measurable radiation below
315 nm. The spectrum exhibits a broad peak across the UVA spectrum with
the majority of the output occurring between 325 and 400 nm.
CAT activity have been achieved by applying 8-MOP twice prior to
UVA treatment. In this study, we determine the sensitivity of our
system in measuring the protection afforded by a sunscreen lotion with
significant UVB and some UVA absorption resulting in a sun protection
factor (SPF) of 15, a predominantly UVA absorbing sunscreen, and a
sunscreen combining the ingredients of the SPF 15 sunscreen and the
UVA filter.
MATERIALS AND METHODS
Transgenic mice expressing the human elastin promoter We utilized a
homozygous line of transgenic mice expressing the 5.2 kb human elastin
promoter, linked to a CAT reporter gene that enables measurement of elastin
promoter activation, as previously described (Hsu-Wong et al, 1994). Although
phenotypically normal, these mice express the human elastin promoter when
assayed for CAT activity (Hsu-Wong et al, 1994; Bernstein et al, 1995, 1996).
Four- or 5-d-old mice were used because at this age visible hair growth, which
could block substantial amounts of UVA, is not yet present.
CAT assay To measure the expression of the human elastin promoter/CAT
reporter gene construct, CAT activity was determined in the skin of transgenic
mice. For extraction of the CAT protein, the specimens were homogenized
using a tissue homogenizer (Brinkmann Instruments, Westbury, NY), and the
homogenates centrifuged prior to the subsequent determination of protein
concentration in the supernatant using a commercial protein assay kit (Bio-Rad
Laboratories, Richmond, CA). Aliquots of the supernatant containing 100 mg
of protein were used for assay of CAT activity by incubation with [14C]chloram-
phenicol as a substrate, as described elsewhere (Hsu-Wong et al, 1994; Bernstein
et al, 1995, 1996). The acetylated and nonacetylated forms of radioactive
chloramphenicol were separated by thin-layer chromatography, and CAT
activity was determined by the radioactivity in the acetylated forms as a
percentage of the total radioactivity in each sample.
UVA source and sunscreens Irradiation with UVA was performed using a
closely spaced array of seven FR40T12 PUVA lamps (Osram Sylvania, Danvers,
MA) filtered through window glass of 2 mm thickness to remove wavelengths
below 320 nm (Fig 1) (Staberg et al, 1983). The energy output 38 cm from
the array was measured with a Solar Light model 3D UVA and UVB detector
(Solar Light, Philadelphia, PA). The output of the lamps filtered through
window glass was 2.02 mW per cm2, with no detectable UVB.
Three sunscreen formulations were tested in our model. We tested a sunscreen
with significant UVB and some UVA absorption with an SPF of 15, a
predominantly UVA absorbing sunscreen, and a sunscreen combining the
ingredients of the SPF 15 product and the UVA filter. The SPF 15 sunscreen
and the combination product contained octyl methoxycinnamate (Hoffmann-
La Roche, Paramus, NJ) and benzophenone-3 (BASF Wyandotte, Parsippany,
NJ), whereas the UVA filter and the combination product contained the UVA
Table I. Key components in sunscreen formulations
Ingredient SPF 15 Parsol Comb.
octyl methoxycinnamate 7.5% 0 7.5%
benzophenone-3 3.0% 0 3.0%
butyl methoxydibenzoylmethane 0 3.0% 3.0%
(Parsol 1789)
filter butyl methoxydibenzoylmethane (Parsol 1789; Hoffmann-La Roche), in
an oil-in-water emulsion (Table I). The SPF 15 sunscreen is a commercial
product shown to have the stated SPF by the protocol established by the Food
and Drug Administration for the testing of sunscreens (Cripps et al, 1982). The
sunscreens containing Parsol 1789 were not subjected to such testing, so formal
SPF values for these products are not available.
Phototreatment Mice were placed under the center of the light array and
restrained, exposing their dorsal surfaces to UVA at a distance of 38 cm from
the fluorescent tubes. Unirradiated control mice were restrained in a similar
manner. Only mice from the same litter were used for each experiment. Two
mice were used for each data point, and experiments were repeated in triplicate,
resulting in six values for each experimental condition. The UVA dose and 8-
MOP concentration used were selected on the basis of previous studies
documenting significant elastin promoter activation at the dose and concentration
used (Bernstein et al, 1996). PUVA-treated mice received 25 µl of an ethanolic
solution containing 2 mg 8-MOP per ml, applied twice to their backs 30 and
22 min before exposure to 10 J UVA per cm2. 8-MOP control mice received
identical topical applications of 8-MOP, but were not exposed to UVA. UVA
control mice received a dose of 10 J UVA per cm2, without prior application
of 8-MOP. Untreated controls were restrained in a identical fashion to treated
mice, but received no 8-MOP or UVA.
Fifteen minutes prior to UVA administration for PUVA treatment, sunscreens
were applied at a concentration of 2 mg per ml and spread evenly over the
dorsal surface of the mice using a glass rod. The concentration was selected by
following recommendations for the testing of sunscreens set forth by the Food
and Drug Administration (1993). PUVA control mice received the lotion
vehicle instead of sunscreen prior to PUVA treatment. The sunscreen-treated
mice received either the SPF 15 sunscreen, the UVA filter, or the combination
SPF 15 sunscreen and UVA filter, after 8-MOP application and prior to
administration of UVA. Following phototreatment, the backs of the mice were
rinsed twice with 70% isopropyl alcohol pads to remove excess 8-MOP, vehicle,
and sunscreen. Mice were sacrificed and skin harvested for determination of
CAT activity 24 h after phototreatment, because this was determined in previous
studies to be the time of maximal promoter activation following treatment
(Bernstein et al, 1995, 1996). For statistical analysis, a paired t test analysis
was performed.
RESULTS
Sunscreens protect against photoaging as measured by elastin
promoter activation in transgenic mice PUVA treatment utilizing
an 8-MOP dose of 2 mg per ml applied twice prior to treatment and
10 J UVA per cm2 administered in a single dose, increased CAT activity
up to about 8-fold that of untreated controls. Sunscreen administration
reduced this increase progressively with the SPF 15 sunscreen, the
UVA filter, and the combination of the SPF 15 sunscreen and the
UVA filter, resulting in increasing protection against PUVA-induced
elastin gene induction (Fig 2). Averaging the three experiments that
were each performed in duplicate, mice receiving PUVA and the
lotion vehicle demonstrated a 8.0 6 0.8-fold (mean 6 SEM) increase
in CAT activity over unirradiated controls, and this increase was
statistically significant (p , 0.0001). Mice receiving the SPF 15
sunscreen, the UVA filter, and the combination sunscreen, demonstrated
a 3.4 6 0.8-fold, 2.4 6 0.7-fold, and 1.2 6 0.3-fold increase in CAT
activity, respectively, relative to untreated controls (Fig 3). This
represents a decrease in CAT activity in all mice receiving sunscreens
followed by PUVA, as compared with those receiving only the lotion
vehicle and PUVA. Thus, sunscreen administration reduced CAT
activity by 57, 70, and 85%, for the SPF 15 sunscreen, the UVA
filter, and the combination sunscreen, respectively. The combination
sunscreen reduced CAT activity to slightly above that of untreated
controls. The vehicle alone resulted in no protection against PUVA
(data not shown), and neither 8-MOP alone, the vehicle, nor any
sunscreen altered CAT activity by themselves without PUVA or UVA
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Figure 2. Sunscreens protect against photoaging as measured by elastin
promoter activation in transgenic mice. Mice were pretreated topically
with 8-MOP prior to sunscreen administration. Mice received either a vehicle
alone containing no sunscreen (PUVA 1 Vehicle), a sunscreen with an SPF of
15 having some absorption in the UVA (PUVA 1 SPF 15), a sunscreen with
significant absorption in the UVA range (PUVA 1 Parsol), or a combination
product combining the ingredients of the SPF 15 sunscreen and the UVA filter
(PUVA 1 comb.). Untreated control mice (cont.) received no topical treatment
or UVA. Increasing amounts of protection were afforded by the SPF 15
sunscreen, the UVA filter, and the combination product, respectively. The
positive control represents an extract from the skin of a transgenic mouse
previously treated with UVB, and known to result in elastin promoter
upregulation. Each lane represents an assay from a separate mouse.
Figure 3. Averaging all experiments, sunscreens offering greater UVA
protection resulted in larger reductions in elastin promoter activity.
PUVA resulted in an 8.0-fold increase in CAT activity (p , 0.0001) on average
in mice treated with vehicle lotion alone (PUVA 1 Vehicle), as compared with
mice receiving no 8-MOP or UVA (cont.). Application of sunscreens in mice
receiving PUVA reduced elastin promoter activity by 57, 70, and 85% for the
SPF 15 sunscreen (PUVA 1 SPF 15), the UVA filter (PUVA 1 Parsol), and the
combination product combining the ingredients of the SPF 15 sunscreen and
the UVA filter (PUVA 1 comb.), respectively. In each case, this reduction was
statistically significant when compared with mice receiving the lotion vehicle
alone followed by PUVA (PUVA 1 Vehicle). Bars indicate mean 6 SEM.
Statistical significance is indicated above the bars (*p 5 0.001; **p , 0.0001).
treatment (data not shown). UVA alone resulted in a µ1.8-fold increase
in CAT activity (data not shown).
DISCUSSION
Significant elastin gene induction was achieved with PUVA in our
transgenic mice and enabled the differentiation of sunscreens affording
increasing amounts of UVA protection. The combination SPF 15 and
UVA filter resulted in a reduction in CAT activity approximately to
the baseline levels of untreated mice. An SPF 15 sunscreen would be
expected to have at least a UVA protection factor of 2 to achieve an
SPF rating of 15 (Diffey, 1990; Agin and Stanfield, 1992; Cole and
VanFossen, 1992b). In our system the SPF 15 sunscreen resulted in a
UVA protection factor of 2.3, agreeing well with this figure. Extending
the protection further into the UVA spectrum by using the UVA filter
Parsol 1789 resulted in an even greater reduction in CAT activity,
with a UVA protection factor of 3.3. The greatest protection was
afforded by the combination sunscreen that reduced CAT activity to
approximately baseline levels. Thus, our system proved to be both
rapid and sensitive, yielding quantitative results sensitive enough to
distinguish between sunscreens with increasing amounts of UVA
protection. In addition, the use of the human elastin promoter in a
transgenic mouse model may more closely simulate cutaneous photoag-
ing in the human than models relying solely on murine responses
to UVA.
Although the ease of use, sensitivity, and reproducibility of using
genetically engineered mice that are identical to one another provide
many advantages, murine skin differs from human skin. The thinness
of mouse skin overemphasizes the effect of shorter wavelengths of
solar radiation that may penetrate into a large portion of the murine
dermis, although reaching only the most superficial layers of the thicker
human dermis. In addition, variations in the murine and human
inflammatory response may be reflected, because humans tend to
develop erythema in response to solar radiation more readily than
mice. The results obtained after administration of UVA alone in the
current experiment are comparable with our previously measured
response to UVA, demonstrating less than a 2-fold increase in CAT
activity versus untreated mice (Bernstein et al, 1995). Thus, the addition
of 8-MOP before UVA treatment resulted in adequate elastin promoter
activation to enable the differentiation of various sunscreens from one
another. Because 8-MOP-induced phototoxicity peaks at the shorter
UVA wavelengths, using PUVA overemphasizes the contribution of
the shorter wavelengths of UVA to elastin gene induction or photoaging,
versus using UVA alone (Cripps et al, 1982; Garmyn and Roelandts,
1992).
Others have used mouse models of UVA-induced photodamage to
measure the degree of solar elastosis resulting from various portions of
the UVA spectrum (Bissett et al, 1989; Wulf et al, 1989; Kligman and
Sayre, 1990), and as a possible method for evaluating products thought
to afford protection from UVA (Barth, 1978; Folsom et al, 1983; Bissett
et al, 1987; Garmyn et al, 1989; Fourtanier et al, 1992; Garmyn and
Roelandts, 1992; Tokura et al, 1994). Action spectra for solar elastosis
generated using murine models have shown that UVA is capable of
producing solar elastosis, although it is significantly less efficient than
UVB at doing so (Bissett et al, 1989; Wulf et al, 1989; Kligman and
Sayre, 1990). Three studies seeking to determine an action spectrum
for the development of solar elastosis differ in their determination of
the relative ability of UVA to induce elastosis (Bissett et al, 1989; Wulf
et al, 1989; Kligman and Sayre, 1990; Sayre and Kligman, 1992). Two
studies demonstrate very little decrease in the ability to induce elastosis
with increasing wavelengths of UVA (Bissett et al, 1989; Wulf et al,
1989), whereas a third study shows a marked reduction in the ability
of longer UVA wavelengths to induce elastosis (Kligman and Sayre,
1990). The latter action spectrum corresponds more closely to the
human erythema action spectrum (Kligman and Sayre, 1990). If longer
wavelengths do indeed contribute much less to the generation of solar
elastosis, the use of 8-MOP in our model may have less importance,
because 8-MOP would emphasize the contribution of the shorter UVA
wavelengths. If the ability of UVA to generate solar elastosis is
relatively constant throughout the UVA spectrum, however, as has
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been demonstrated for some dermal responses to UVA including
lysozyme deposition and dermal inflammation (Lavker and Kaidbey,
1997), the increased absorption of 8-MOP toward the shorter UVA
wavelengths might have more importance.
Studies using mouse models to evaluate the UVA protection afforded
by sunscreens have measured several cutaneous responses to UVA.
These responses include: edema (Barth, 1978; Garmyn and Roelandts,
1992), formation of sunburn cells (Garmyn et al, 1989), induction of
epidermal ornithine decarboxylase (Folsom et al, 1983), induction of
contact allergy (Tokura et al, 1994), hyperkeratosis (Fourtanier et al,
1992), wrinkling (Fourtanier et al, 1992), skin sagging (Bissett et al,
1987; Fourtanier et al, 1992), skin fold thickness (Bissett et al, 1987),
and extracellular matrix alterations including changes in elastic fibers
(Bissett et al, 1987; Fourtanier et al, 1992). Many of the above models
measure epidermal alterations (Folsom et al, 1983; Fourtanier et al,
1992; Tokura et al, 1994), which may have a different spectral
dependence than the dermal changes leading to the sagging and
wrinkling that characterize photoaged skin (Lavker and Kaidbey, 1997).
Others, such as induction of contact allergy (Tokura et al, 1994) or
generation of edema (Barth, 1978; Garmyn and Roelandts, 1992), may
not correlate with UVA-induced aging. Models testing UVA sunscreens
and measuring skin responses thought to correlate more closely with
cutaneous photoaging, such as wrinkling, skin sagging, and elastic fiber
alterations, utilized UVA exposure times from 33 wk to 1 y (Bissett
et al, 1987; Fourtanier et al, 1992). Most of the murine models that
measured more immediate responses to UVA used photosensitizers,
such as 8-MOP (Barth, 1978; Folsom et al, 1983; Garmyn et al, 1989;
Garmyn and Roelandts, 1992) or another photosensitizer (Tokura et al,
1994), to generate a brisk response to UVA. In this study we utilize
8-MOP to enhance the promoter induction occurring in response to
UVA alone, thus increasing the degree of sensitivity obtainable in
our system.
Because the development of solar elastosis in humans as a result of
chronic solar radiation takes decades, other measures of skin damage
must be used when testing sunscreens and other UVA-protective agents
on humans. Parameters measured in unsensitized subjects include
erythema (Kaidbey and Gange, 1987; Stanfield et al, 1989; Cole and
VanFossen, 1992b; Cole, 1994), delayed tanning (Kaidbey and Gange,
1987; Roelandts et al, 1989; Cole and VanFossen, 1992b; Cole, 1994),
and immediate pigment darkening (Kaidbey and Gange, 1987; Kaidby
and Barnes, 1991). In subjects receiving 8-MOP prior to UVA
administration, the endpoints were development of 8-MOP phototox-
icity as measured by erythema (Farratt et al, 1983; Gange et al, 1986;
Kaidbey and Gange, 1987; Lowe et al, 1987; Roelandts et al, 1989)
and delayed tanning (Gange et al, 1986). Our results using the transgenic
mouse model of photoaging compare quite favorably with those
measured in humans receiving 8-MOP. Kaidbey and Gange recorded
a UVA protection factor of 3.5 for a formulation containing 3% Parsol
1789 (Kaidbey and Gange, 1987), whereas a similar 3% formulation
yielded a UVA protection factor of 3.3 in our murine system. Thus,
it is possible that the factors responsible for induction of phototoxicity
in humans are similar to those resulting in elastin gene induction in
our mouse model. Inflammation may indeed play a role in elastin gene
induction by UVA as measured in our mouse model. Although we
recorded a very large increase in CAT activity after exposure of
fibroblast cultures derived from the skin of transgenic mice to UVB,
no corresponding increase was measured after relatively large doses of
UVA, despite an increase in CAT activity in vivo after UVA exposure
(Bernstein et al, 1995). These results suggest that inflammation may
play a role in regulating the response of the human elastin promoter
to UVA, and that cells other than dermal fibroblasts may be the initial
target leading to UVA-induced gene induction.
Increasing awareness of the deleterious effects of solar radiation,
especially its contribution to cutaneous photoaging, has resulted in the
use of sunscreens with higher SPF ratings. To obtain these higher SPF,
increasing amounts of UVA protection must be incorporated into the
sunscreens (Cole and VanFossen, 1992a). As sunscreens with filters that
absorb in the UVB and near UVA range are used, the amount of
ultraviolet radiation actually reaching the skin will be composed of the
longer wavelengths of UVA (Cole and VanFossen, 1992a). Even
suberythemogenic doses of UVA can result in signs of sun-damage,
including epidermal hyperplasia, sunburn cell formation, the depletion
of Langerhans cells, induction of erythema and inflammation, and
extracellular matrix alterations (Lavker et al, 1995a, b; Lowe et al,
1995). Many such changes, including increases in epidermal thickness,
inflammation, and lysozyme deposition on elastic fibers, were elicited
by long waveband UVA equally as well as broad band UVA (Lavker
et al, 1995b;Lavker and Kaidbey, 1997). These findings suggest that
UVA filters with increasing effectiveness in the long UVA wavebands
may be necessary to better prevent sun-induced photoaging. Our
murine model of photoaging is the first to use genetically engineered
animals to increase the sensitivity of the system. With it, we can rapidly
screen agents thought to afford protection against UVA, and compare
new agents with those known to prevent UVA-induced photoaging.
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